Using test results to improve outcomes after organ or marrow transplant
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at “biomarkers,” which are measurable lab signals, in people who have had an organ or bone marrow transplant. The goal is to use these test results to better predict and improve transplant outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had an abdominal, chest (thoracic), or bone marrow transplant (called an allograft)
- You are getting follow-up care as an inpatient and/or outpatient with routine lab tests at UPMC
- You (or your parent/guardian) can read and understand the informed consent form
- All ages are allowed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is following people who have had a liver, kidney, heart, or lung transplant. It will look for markers in your blood that might help predict how you do in the short and long term after transplant.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
This study looks at whether a specialized blood test can help doctors better assess lung cancer. It may be helpful if you are an adult who can safely participate and provide a sample for testing.
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Hear when a new Solid Organ Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.